Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial
- PMID: 15317642
- DOI: 10.1111/j.1360-0443.2004.00814.x
Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial
Abstract
Background: Previous published studies assessed the efficacy of bupropion in smoking cessation only in North American populations of smokers. Results of therapeutic drug trials are not always directly applicable in other populations.
Aims: To confirm the efficacy of bupropion in smoking cessation in European smokers.
Design: A multi-centre, randomized, double-blind placebo-controlled trial.
Setting: Seventy-four smoking cessation out-patient clinics in France.
Participants: The study included 509 smokers motivated to quit smoking. Intervention Subjects were randomized to either slow-release bupropion 150 mg b.i.d. (B) or to placebo (Pl) in a 2 : 1 ratio, treated for 7 weeks, and followed-up for 26 weeks.
Main outcome measure: 6 months' point prevalence abstinence, determined by self-report and expired air carbon monoxide measurement.
Secondary outcome measures: weeks 4-7 and weeks 4-26 continuous abstinence rates, craving, withdrawal symptoms, weight and cigarette consumption in smokers unable to quit. Adverse events were recorded systematically.
Findings: Six months' point prevalence abstinence rates were 31% and 16%[odds ratio = 2.3, confidence interval (CI) 95%: 1.4-3.7] in the B and Pl groups, respectively. Continuous abstinence rates were 41% (B) and 21% (P) with OR = 2.5 (CI 95%: 1.6-3.9) for weeks 4-7, and 25% (B) and 13% (P) with OR = 2.2 (CI 95%: 1.3-3.6) for weeks 4-26, respectively. Craving decreased significantly more with B than with Pl during treatment period, but there was no difference for total withdrawal symptoms score. Abstinent subjects gained significantly less weight at week 7 with B than with Pl. Low level of nicotine dependence, high motivation, absence of smoking-related disease, long duration of previous quit attempts, male gender, low level of current alcohol problems and living as a couple were predictive of successful cessation. With the exception of marital status, no interaction was observed between any of these predictive factors and the efficacy of bupropion. More of those who continued smoking in the B group than the P group reduced their consumption by at least 50%.
Conclusions: Sustained-release bupropion is efficacious as an aid to smoking cessation in European smokers. No outcome predictors were identified that might indicate that certain subgroups of smokers would benefit more than others from treatment with bupropion.
Similar articles
-
A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees.Nicotine Tob Res. 2004 Feb;6(1):55-61. doi: 10.1080/14622200310001656867. Nicotine Tob Res. 2004. PMID: 14982688 Clinical Trial.
-
Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.JAMA. 2006 Jul 5;296(1):56-63. doi: 10.1001/jama.296.1.56. JAMA. 2006. PMID: 16820547 Clinical Trial.
-
A comparison of sustained-release bupropion and placebo for smoking cessation.N Engl J Med. 1997 Oct 23;337(17):1195-202. doi: 10.1056/NEJM199710233371703. N Engl J Med. 1997. PMID: 9337378 Clinical Trial.
-
Bupropion: a review of its use in the management of smoking cessation.Drugs. 2000 Apr;59(4):1007-24. doi: 10.2165/00003495-200059040-00019. Drugs. 2000. PMID: 10804045 Review.
-
Use of sustained-release bupropion in specific patient populations for smoking cessation.Drugs. 2002;62 Suppl 2:37-43. doi: 10.2165/00003495-200262002-00004. Drugs. 2002. PMID: 12109934 Review.
Cited by
-
Sex effects in predictors of smoking abstinence and neuropsychiatric adverse events in the EAGLES trial.Drug Alcohol Depend Rep. 2023 Jul 12;8:100177. doi: 10.1016/j.dadr.2023.100177. eCollection 2023 Sep. Drug Alcohol Depend Rep. 2023. PMID: 37520849 Free PMC article.
-
Antidepressants for smoking cessation.Cochrane Database Syst Rev. 2023 May 24;5(5):CD000031. doi: 10.1002/14651858.CD000031.pub6. Cochrane Database Syst Rev. 2023. PMID: 37230961 Free PMC article. Review.
-
Interventions for preventing weight gain after smoking cessation.Cochrane Database Syst Rev. 2021 Oct 6;10(10):CD006219. doi: 10.1002/14651858.CD006219.pub4. Cochrane Database Syst Rev. 2021. PMID: 34611902 Free PMC article. Review.
-
Antidepressants for smoking cessation.Cochrane Database Syst Rev. 2020 Apr 22;4(4):CD000031. doi: 10.1002/14651858.CD000031.pub5. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2023 May 24;5:CD000031. doi: 10.1002/14651858.CD000031.pub6. PMID: 32319681 Free PMC article. Updated.
-
Modelling continuous abstinence rates over time from clinical trials of pharmacological interventions for smoking cessation.Addiction. 2019 May;114(5):787-797. doi: 10.1111/add.14549. Epub 2019 Jan 29. Addiction. 2019. PMID: 30614586 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources